Tudor Investment Corp’s Quince Therapeutics QNCX Stock Holding History

Tudor Investment Corp’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-16	Closed	-$294K	–	2890
2021 Q3	$294K	Buy	+16	New	+$254K	﹤0.01%	2054

Other funds holding QNCX

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Tudor Investment Corp's QNCX Position: Q4 2021 in Review

Tudor Investment Corp sold out of Quince Therapeutics (QNCX) in Q4 2021, closing a stake of 16 shares — an estimated $294K sold.

Tudor Investment Corp first reported a position in QNCX in Q3 2021 and held it in 1 quarter. The position peaked at $294K in Q3 2021. 97 funds tracked by Wall St. Rank hold QNCX as of Q4 2021.

Tudor Investment Corp reported no remaining Quince Therapeutics position as of Q4 2021 after selling out during the quarter.
Tudor Investment Corp sold 16 Quince Therapeutics shares in Q4 2021, an estimated $294K.
Tudor Investment Corp first reported a position in Quince Therapeutics in Q3 2021 and held it in 1 quarter.
Tudor Investment Corp's Quince Therapeutics position peaked at $294K in Q3 2021.
97 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2021.

Based on Tudor Investment Corp's 13F filing for Q4 2021, filed 14 Feb 2022.